Metastatic renal cancer immunotherapy versus targeted therapy


MUDr. Jindřich Kopecký, Ph.D.

Klinika onkologie a radioterapie LF UK a FN, Hradec Králové



In the last decade, we are witnesses of great development and improvement in renal cancer therapy. Based on better understanding of the mechanisms of pathogenesis and the improvement in immunotherapy, we are able to reach long-term responses. Currently, it is still not clear, if there is a choice of, which drug to use. We do not always have head to head comparisons of drugs. In our conditions is this issue partially artificially simplified due to reimbursement. The following article discusses the current status, advantages and disadvantages of immunotherapy and targeted therapy in renal cancer.


Key words

renal carcinoma, immunotherapy, targeted therapy, cabozantinib, nivolumab



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...